Late last year, Owlstone Medical Ltd. made a deal with Glaxosmithkline plc to include its breath biopsy system in a phase II trial for a chronic obstructive pulmonary disorder (COPD) candidate. The latest pharma deal for the Cambridge, U.K.-based startup is with Astrazeneca plc and also in respiratory, but this time the partnership is a bit more expansive, covering the identification of biomarkers related to disease phenotypes that are relevant in asthma and COPD. Read More
